---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-022291"
form_type: "8-K"
ticker: "SMTI"
cik: "0000714256"
company_name: "Sanara MedTech Inc."
filed_at: "2026-05-11T21:21:56+00:00"
generated_at: "2026-05-11T21:26:33.622899+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Sanara MedTech Q1 net revenue up 19% to $27.8M; GAAP EPS $0.04 vs ($0.07) loss

## Summary
- Net income from continuing ops of $0.4M ($0.04 diluted EPS) vs loss of $0.6M ($0.07) YoY.
- Adjusted EBITDA $4.3M (+58% YoY); gross margin improved to 93% from 92%.
- Soft tissue repair revenue rose 21% to $24.9M; bone fusion revenue essentially flat at $2.9M.
- Q2 2026 revenue guidance $28.5M-$29.5M (10-14% growth); full-year 2026 reaffirmed at $116M-$121M.
- Sales team expanded to 43 reps; products contracted at >4,000 U.S. facilities; cash $13.6M, debt $46.2M.

## SEC filing metadata
- accession: 0001493152-26-022291
- form_type: 8-K
- ticker: SMTI
- cik: 0000714256
- company_name: Sanara MedTech Inc.
- filed_at: 2026-05-11T21:21:56+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/0001493152-26-022291-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-022291
- JSON: https://secwatch.observer/filing/0001493152-26-022291.json
- Plain text: https://secwatch.observer/filing/0001493152-26-022291.txt

## Key facts
- Earnings Releases
  Sanara MedTech Inc. reported the first quarter ended March 31, 2026 results: revenue $27.8 million, net income $0.4 million, EPS $0.04 per diluted share.
  - Period: the first quarter ended March 31, 2026
  - Revenue: $27.8 million
  - Net income: $0.4 million
  - EPS: $0.04 per diluted share
  - Result: reported results
  source text: in the surgical market, today reported its financial results for the first quarter ended March 31, 2026. First Quarter 2026 Financial Summary (1) ● Net revenue increased 19% to $27.8 million, compared to $23.4 million in the first quarter of 2025. ● Gross profit of $25.9 million, or 93% of net revenue, compared to gross profit of $21.6 million, or 92% of net
  evidence_url: https://www.sec.gov/Archives/edgar/data/714256/000149315226022291/0001493152-26-022291-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.